Our study demonstrates that inhibition of EGFR with C225 enhances cytotoxicity with the PARPi ABT-888 in head and neck cancer cells via C225-mediated disruption of the HR- and NHEJ-mediated DSB repair pathways. The gene discussed is EGFR; the disease is head and neck cancer.